VYNE – vyne therapeutics inc. (US:NASDAQ)

News

VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
VYNE Therapeutics receives FDA approval for trial of VYN202 [Yahoo! Finance]
VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com